Roche takes on Loxo, Bayer in gene-defined cancer class

Roche's entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news